Kiadis Pharma N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
20 oct 2015 - 07:00
Statutory name
Kiadis Pharma N.V.
Title
Kiadis Pharma announces enrolment of first patient in its repeat-dosing Phase II clinical trial with ATIR101™
Comments
Amsterdam, The Netherlands, October 20, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the first patient has been enrolled into its repeat-dosing Phase II clinical trial, CR-AIR-008, with its lead product ATIR101™. The patient was enrolled in Hamilton, Canada within a month of receiving regulatory approval for the study from the Canadian authorities.
Date last update: 05 April 2026